Coherus BioSciences (NASDAQ:CHRS) Earns “Buy” Rating from HC Wainwright
HC Wainwright restated their buy rating on shares of Coherus BioSciences (NASDAQ:CHRS – Free Report) in a research note released on Monday, Benzinga reports. HC Wainwright currently has a $12.00 target price on the biotechnology company’s stock. HC Wainwright also issued estimates for Coherus BioSciences’ Q4 2024 earnings at ($0.25) EPS and FY2024 earnings at […]
19 Sep 06:06 · The Markets Daily